Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical Ltd has announced positive preliminary results from its PANCOSIL Phase 1-2 study, which demonstrates the safety and feasibility of delivering the OncoSil™ device via CT-guided percutaneous administration for treating locally advanced pancreatic cancer. The study showed a 90% technical success rate and a median overall survival of 20.6 months, surpassing the typical 13 months for LAPC. These findings could lead to further regulatory approvals and expand the use of OncoSil™ therapy, potentially transforming treatment delivery and increasing adoption in clinical practice.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a company specializing in pancreatic cancer treatment devices. It focuses on developing innovative therapies for locally advanced pancreatic cancer (LAPC) using its OncoSil™ device, which is designed for minimally invasive oncology treatments.
Average Trading Volume: 41,802
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$30.12M
See more insights into OSL stock on TipRanks’ Stock Analysis page.